Nivalis Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2
Founded: Boulder CO United States (2007)
Status: Acquired by Alpine Immune Sciences (2017)

Organization Overview

First Clinical Trial
2010
NCT01147406
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

cavosonstat (7 trials)

danegaptide (1 trial)

Drugs in Phase 1 Trials (3)

n6022 (3 trials)

rifampin (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 5